Unknown

Dataset Information

0

Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort—the smile study

ABSTRACT:

SUBMITTER: Auclin E 

PROVIDER: S-EPMC12337063 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.
| S-EPMC8205932 | biostudies-literature
Unknown Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance.
| S-EPMC11875782 | biostudies-literature
Unknown Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases.
| S-EPMC6825912 | biostudies-literature
Unknown Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib.
| S-EPMC10682450 | biostudies-literature
Unknown ACTN4 Gene Amplification and Actinin-4 Protein Expression for Osimertinib Efficacy in EGFR-Mutant NSCLC.
| S-EPMC12666467 | biostudies-literature
Unknown Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
| S-EPMC5932243 | biostudies-literature
Unknown The novel BET degrader, QCA570, is highly active against the growth of human NSCLC cells and synergizes with osimertinib in suppressing osimertinib-resistant EGFR-mutant NSCLC cells.
| S-EPMC8900006 | biostudies-literature
Unknown Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients.
| S-EPMC11832947 | biostudies-literature
Unknown Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib.
| S-EPMC7004431 | biostudies-literature
Unknown A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With <i>EGFR</i>-Mutant NSCLC.
| S-EPMC9445370 | biostudies-literature